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Resident memory T cells (TRM) comprise a subset of non-recirculating memory T cells that remain positioned at common portals of re-infection. These include barrier tissues 
such as the mucosae and skin. TRM orchestrate the initial response to pathogens re-encountered at these locales, thereby accelerating protective immune responses.
Defining TRM
When naive T cells are stimulated by pathogens within secondary lymphoid organs, they proliferate and differentiate into effector T cells, many of which home to nonlym-
phoid tissues. Following clearance of the infection, a fraction of pathogen-specific T cells differentiate into long-lived memory T cells. Memory T cells can be divided into three 
operationally distinct subsets based on trafficking properties (upper-left). Central memory T cells (TCM) recirculate between lymph nodes, lymph, and blood. Effector memory 
T cells (TEM) recirculate between certain nonlymphoid tissues, lymph (transiently passing through lymph nodes), and blood. However, some tissues, including many epithelial 
surfaces, are excluded from routine immune surveillance by recirculating TCM and TEM. Instead, these tissues are populated by a distinct lineage of memory T cells recently 
termed TRM. TRM are constitutively poised for rapid effector function and have been identified within many barrier tissues (Cauley and Lefrançois, 2013).
The defining signature of TRM is their persistence within a single anatomic compartment without recirculating. TRM do not exit tissues, enter circulation, and then reenter tis-
sues. Rather, they remain stationed within one locale. One definitive experimental approach that informs whether a population of memory T cells is resident versus recirculat-
ing utilizes parabiosis (conjoining two animals so that they develop a shared circulatory system) and monitoring memory T cell movement between host tissues (Klonowski et 
al., 2004). Due to the challenges associated with performing this assay, T cell phenotype is typically used as a surrogate for identifying TRM (right), although characterization 
and validation of a lineage-defining TRM phenotype remains an area of active inquiry.
TRM Ontogeny and Differentiation
Effector T cells express combinations of chemokine receptors, selectins, and/or integrins in order to extravasate from blood and enter nonlymphoid tissues. Different non-
lymphoid tissues have distinct entry requirements. For example, T cells express α4β7 and CCR9 to enter small intestine and PSGL-1 and CCR10 or CCR4 to enter skin (upper-
left). Following infection clearance, some effectors differentiate into long-lived memory T cells. Importantly, the location where memory development occurs directly shapes 
their differentiation program. TRM adopt signatures that distinguish them from TCM and TEM (right). These developmental cues are encountered within the tissues patrolled by 
TRM, may contribute to TRM survival and site-specific retention, and may include TGFβ, IL-15, IL-33, and TNFα (Casey et al., 2012; Mackay et al., 2013). TRM signatures include 
expression of CD69 and reduced expression of the transcription factors KLF2 and Eomes as well as the lymph node homing molecule CD62L. A subset of CD8+ TRM, par-
ticularly those resident within epithelial surfaces of the intestinal mucosa and skin, also express αEβ7 integrin (often referred to as CD103, an alternative term for αE), which is 
induced by local TGFβ. Many TRM constitutively express granzyme B and remain poised for rapid antipathogen function.
It should be noted that TRM are not terminally differentiated. In mice, they arise from KLRG1
lo effector T cells, a subset of effectors that still exhibits developmental plasticity 
(Mackay et al., 2013). Moreover, if TRM are experimentally removed from the anatomic compartment in which they reside, they can be reprogrammed to differentiate into TCM 
and TEM (Masopust et al., 2006).
Mechanisms of TRM Survival and Stasis
Most TRM characterized thus far express CD69. CD69 expression indicates that cells are refractory to sphingosphine-1 phosphate (S1P) signals, which attract lymphocytes 
to leave tissues via the lymph. TRM also downregulate a critical S1P receptor, S1P1. Reports indicate that either downregulation of S1P1 or upregulation of CD69 is required to 
establish or maintain TRM in barrier tissues (lower-middle) (Mackay et al., 2013; Skon et al., 2013).
αEβ7 integrin binds to E-cadherin expressed by epithelial cells. Induction of αEβ7 integrin expression is required for the maintenance of TRM in the small intestine epithelium, 
where epithelial cells are replaced every 4–5 days, as well as many other compartments (Casey et al., 2012; Mackay et al., 2013; Lee et al., 2011). αEβ7 integrin can also be 
expressed by T cells in some locations where it appears dispensable for maintenance (e.g., the small intestinal lamina propria) yet is not expressed by TRM in many locations 
(Casey et al., 2012). To make matters more complicated, recirculating naive and regulatory T cells also express αEβ7 integrin. Thus, αEβ7 integrin expression is a useful, but not 
unequivocal, marker of TRM.
The cytokine IL-15 is important for the survival and continued basal “homeostatic” (not pathogen-driven) proliferation of TCM. IL-15 has also been shown to be important 
for the establishment of long-lived TRM within the epidermis (Mackay et al., 2013). Paradoxically, TRM in many locations express unusually low levels of the IL-15 receptor and 
fail to undergo homeostatic proliferation (Masopust et al., 2006; Gebhardt et al., 2009). So, the precise role of IL-15 in the formation and maintenance of TRM in many locations 
remains to be elucidated.
Function of TRM
T cells must contact host cells to recognize infection and execute functions. TRM in barrier tissues can accelerate infection control when pathogens are re-encountered at 
these body surfaces (Gebhardt et al., 2009; Jiang et al., 2012; Teijaro et al., 2011). TRM are positioned for immediate pathogen interception, which precedes the lengthy process 
of reactivation of TCM within downstream secondary lymphoid organs followed by proliferation, redifferentiation, and migration of TCM progeny to the site of infection (lower-left). 
TRM contribution to protective immunity may be mediated by direct cytotoxicity of infected host cells by effector cytokine production or by contributing to the recruitment of 
recirculating memory T cells to the site of infection.
It should be noted that the range of TRM functions within tissues has not been thoroughly characterized and remains a critical area for further inquiry. Additionally, the 
longevity of TRM within tissues is unknown, though evidence from mice and rhesus macaques indicates that they may persist for at least 1–2 years. Identification of strategies 
that optimize TRM establishment after vaccination could potentially pay dividends for protecting against pathogens encountered at body surfaces, including HIV and Mycobac-
terium tuberculosis.
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